Thorbald van Hall

11.4k citations

127 papers · 8.1k indexed · 4 hit papers · h-index 47

Impact in

Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immune cells in cancer
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research

Papers in

Immunology 109
- Immunotherapy and Immune Responses 76
- Immune Cell Function and Interaction 53
- T-cell and B-cell Immunology 32
- Immune cells in cancer 16
Oncology 57
- Cancer Immunotherapy and Biomarkers 34
- CAR-T cell therapy research 32

Co-authors: Sjoerd H. van der Burg Ferry Ossendorp Cornelis J.M. Melief Ramon Arens Rienk Offringa Marjolein Sluijter Elien M. Doorduijn Federico Garrido
Journals: The Journal of Immunology (14 papers)Journal for ImmunoTherapy of Cancer (11 papers)The Journal of Experimental Medicine (6 papers)OncoImmunology (5 papers)International Journal of Cancer (5 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Thorbald van Hall

126 papers receiving 8.0k citations

Hit Papers

align trajectories log scale

Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy 2024 · 72 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 Cancer Cell
2016 Current Opinion in Immunology
2016 Nature reviews. Cancer
2015 Journal of Clinical Investigation

Peers

Countries citing papers authored by Thorbald van Hall

Since Specialization

Citations

This map shows the geographic impact of Thorbald van Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thorbald van Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thorbald van Hall more than expected).

Fields of papers citing papers by Thorbald van Hall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thorbald van Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thorbald van Hall. The network helps show where Thorbald van Hall may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thorbald van Hall, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thorbald van Hall Line = papers co-authored together Thorbald van Hall links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies Cancer Immunology Research ·Christianne Groeneveldt, 高濱照, Wladysław Krajewski, 酒井貴史, Г.Г. ЕЛИСЕЕВ, Diana J.M. van den Wollenberg, Rob C. Hoeben, Matt Coffey, Houra Loghmani, Els M.E. Verdegaal, Marij J.P. Welters, Sjoerd H. van der Burg, Thorbald van Hall, Nadine van Montfoort	2024	3
2	Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy Journal for ImmunoTherapy of Cancer ·Marit J van Elsas, Г.Г. ЕЛИСЕЕВ, Anders Etzerodt, Pornpimol Charoentong, Yifan Jin, Thorbald van Hall, Sjoerd H. van der Burg	2023	17
3	Socs1-knockout in skin-resident CD4+ T cells in a protracted contact-allergic reaction results in an autonomous skin inflammation with features of early-stage mycosis fungoides Biochemistry and Biophysics Reports ·Yixin Luo, Maarten H. Vermeer, Sanne de Haan, 高濱照, Frank R. de Gruijl, Thorbald van Hall, Cornelis P. Tensen	2023	3
4	Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy Journal for ImmunoTherapy of Cancer ·Christianne Groeneveldt, 高濱照, Yifan Jin, Г.Г. ЕЛИСЕЕВ, Wladysław Krajewski, Marjolein Sluijter, Diana J.M. van den Wollenberg, Rob C. Hoeben, Joke M. M. den Haan, Sjoerd H. van der Burg, Thorbald van Hall, Nadine van Montfoort	2022	8
5	Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome Blood ·José David Vivanco Martínez, Cornelis P. Tensen, Alita J. van der Sluijs‐Gelling, Cristina Teodósio, Davy Cats, Hailiang Mei, Tijana Petek, Jun Fang, Willem H. Zoutman, Thorbald van Hall, Alberto Órfão, Júlia Almeida, Jacques J. M. van Dongen, Maarten H. Vermeer	2021	29
6	Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy Journal for ImmunoTherapy of Cancer ·Christianne Groeneveldt, 高濱照, Diana J.M. van den Wollenberg, H. Francis Ha Vas, Jim Middelburg, Dana A. M. Mustafa, Rob C. Hoeben, Sjoerd H. van der Burg, Thorbald van Hall, Nadine van Montfoort	2020	46
7	The NKG2A–HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment Clinical Cancer Research ·Afke Jonker, Sjoerd H. van der Burg, Thorbald van Hall	2020	154
8	Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses Trends in Immunology ·Christianne Groeneveldt, Thorbald van Hall, Sjoerd H. van der Burg, Peter ten Dijke, Nadine van Montfoort	2020	55
9	A herpesvirus encoded Qa-1 mimic inhibits natural killer cell cytotoxicity through CD94/NKG2A receptor engagement eLife ·Xiaoli Wang, Sytse J. Piersma, Christopher A. Nelson, Ya-Nan Dai, 許婷婷, Eric Lazear, Liping Yang, Marjolein Sluijter, Thorbald van Hall, Ted H. Hansen, Wayne M. Yokoyama, Daved H. Fremont	2018	7
10	Identification of non-mutated neoantigens presented by TAP-deficient tumors The Journal of Experimental Medicine ·Koen A. Marijt, Lei Tian, Els M.E. Verdegaal, Michel G.D. Kester, Daniel J. Kowalewski, Hans‐Georg Rammensee, Stefan Stevanović, Mirjam H.M. Heemskerk, Sjoerd H. van der Burg, Thorbald van Hall	2018	53
11	Digital PCR-Based T-cell Quantification–Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma Molecular Cancer Research ·Mark J. de Lange, Ares Osborn, Christine Rains, Mieke Versluis, Ekaterina S. Jordanova, Gré P.M. Luyten, Martine J. Jager, Sjoerd H. van der Burg, Willem H. Zoutman, Thorbald van Hall, Pieter A. van der Velden	2018	33
12	CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy Cancer Immunology Research ·Elien M. Doorduijn, Marjolein Sluijter, Daniela Salvatori, B. Drewniok, Saskia Maas, Ramon Arens, Ferry Ossendorp, Sjoerd H. van der Burg, Thorbald van Hall	2017	36
13	Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy Cancer Immunology Research ·Floris Dammeijer, Lysanne A. Lievense, N. S. Zablotskaya, Menno van Nimwegen, Koen Bezemer, Joost P. Hegmans, Thorbald van Hall, Rudi W. Hendriks, Joachim G.J.V. Aerts	2017	123
14	The MHC Class I Cancer-Associated Neoepitope Trh4 Linked with Impaired Peptide Processing Induces a Unique Noncanonical TCR Conformer The Journal of Immunology ·Dominicus Husada, Elien M. Doorduijn, Adil Doganay Duru, 曹耀宇, Cláudia C. Oliveira, Tatyana Sandalova, Thorbald van Hall, Adnane Achour	2016	12
15	Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression Cancer Immunology Research ·Tetje C. van der Sluis, Marjolein Sluijter, Suzanne van Duikeren, Brian L. West, Cornelis J.M. Melief, Ramon Arens, Sjoerd H. van der Burg, Thorbald van Hall	2015	70
16	Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab Clinical Cancer Research ·Jan Pander, Moniek Heusinkveld, Tahar van der Straaten, Ekaterina S. Jordanova, Renée Baak-Pablo, Hans Gelderblom, Hans Morreau, Sjoerd H. van der Burg, Henk‐Jan Guchelaar, Thorbald van Hall	2011	87
17	Peptide Vaccination after T-Cell Transfer Causes Massive Clonal Expansion, Tumor Eradication, and Manageable Cytokine Storm Cancer Research ·Long V. Ly, Marjolein Sluijter, Mieke Versluis, Gré P.M. Luyten, Sjoerd H. van der Burg, Cornelis J.M. Melief, Martine J. Jager, Thorbald van Hall	2010	40
18	The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects The Journal of Experimental Medicine ·Cláudia C. Oliveira, Peter A. van Veelen, Bianca Querido, Arnoud de Ru, Marjolein Sluijter, Sandra Laban, Jan W. Drijfhout, Sjoerd H. van der Burg, Rienk Offringa, Thorbald van Hall	2009	78
19	Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100 Cancer Research ·Marianne J.B. van Stipdonk, Hong Lan, Marjolein Sluijter, Rienk Offringa, Thorbald van Hall, Adnane Achour	2009	72
20	DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells Cancer Research ·Mattias Carlsten, Niklas K. Björkström, Håkan Norell, Yenan T. Bryceson, Thorbald van Hall, Bettina C. Baumann, Mikael Hanson, Kjell Schedvins, Rolf Kiessling, Hans‐Gustaf Ljunggren, Karl‐Johan Malmberg	2007	189

About Thorbald van Hall

Thorbald van Hall is a scholar working on Immunology, Oncology, Radiology, Nuclear Medicine and Imaging, Ophthalmology and Virology, having authored 127 papers that have together received 8.1k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (76 papers), Immune Cell Function and Interaction (53 papers), Cancer Immunotherapy and Biomarkers (34 papers), CAR-T cell therapy research (32 papers), T-cell and B-cell Immunology (32 papers), Monoclonal and Polyclonal Antibodies Research (20 papers), Immune cells in cancer (16 papers) and Virus-based gene therapy research (10 papers). The work is most often cited by research in Immunology (6.1k citations), Oncology (4.1k citations), Molecular Biology (2.5k citations), Ophthalmology (265 citations) and Biotechnology (234 citations). Thorbald van Hall has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Sjoerd H. van der Burg, Ferry Ossendorp, Cornelis J.M. Melief, Ramon Arens, Rienk Offringa, Marjolein Sluijter, Elien M. Doorduijn, Federico Garrido, Natalia Aptsiauri and Ángel M. García‐Lora. Their work appears in journals such as The Journal of Immunology, Journal for ImmunoTherapy of Cancer, The Journal of Experimental Medicine, OncoImmunology and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact